Pembrolizumab plus enzalutamide and androgen deprivation therapy versus placebo plus enzalutamide and androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: the randomized, double-blind, phase III KEYNOTE-991 study
乔垣结衣
8天前
29
20
已完结
1. 系统已在2025-06-03 11:30:03对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI: 10.1016/j.annonc.2025.05.008
文献链接: https://linkinghub.elsevier.com/retrieve/pii/S0923753425002005
其他信息:
出版社: Elsevier BV
作者: C. Gratzke; M. Özgüroğlu; A. Peer; M.A.N. Sendur; M. Retz; J.C. Goh; W. Loidl; G. Jayram; S.-S. Byun; C. Kwak; M. Kwiatkowski; R.M. Kopp; J.C.V. Limón; J.F.E. Penagos; U. De Giorgi; K.M. da Trindade; C. Niu; Y. Liu; C.H. Poehlein; J.M. Piulats
